What Happened
Market Underperformance And Cautious IPO Window Characterize First Quarter
The medtech sector faced significant challenges in Q1 2026, with equities broadly underperforming major market indexes due to macro headwinds, including the Iran conflict and AI-driven valuation fears. Despite this, companies like Johnson & Johnson, Quest Diagnostics, and Labcorp posted positive returns, driven by their stable, recurring revenue models. The sector also saw structural shifts, with J&J planning to separate its orthopedics business, and a cautious IPO window, with companies like HeartFlow and BillionToOne posting negative YTD returns. This report was summarized from PitchBook’s Q1 2026 Medtech Public Comp Sheet and Valuation Guide.